How cancer cells use repetitive elements to evade immune therapy
Regulation of repetitive elements in cancer by P53 and epigenetic mechanisms
This study is looking at how certain parts of our DNA can affect the immune system's ability to fight ovarian cancer, and it hopes to find ways to make treatments work better for patients by understanding the role of a specific gene called P53.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11043354 on NIH RePORTER |
What this research studies
This research investigates the role of repetitive elements in cancer, particularly ovarian cancer, and how they affect the immune system's ability to target tumors. By using DNA methylation and histone deacetylase inhibitors, the study aims to enhance immune signaling in tumors, making them more susceptible to treatments like anti-PD-1 therapy. The research focuses on understanding how mutations in the P53 gene influence these mechanisms and the overall response to immunotherapy. Patients may benefit from insights that could lead to more effective cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ovarian cancer, particularly those who have not responded to existing immunotherapies.
Not a fit: Patients with early-stage ovarian cancer or those whose cancer is not driven by P53 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for ovarian cancer patients, potentially increasing survival rates.
How similar studies have performed: Previous research has shown promise in using epigenetic modifications to enhance immune responses in cancer, suggesting a potential for success in this approach.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Chiappinelli, Katherine B — George Washington University
- Study coordinator: Chiappinelli, Katherine B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.